Confo Therapeutics’ technology stabilizes functional conformations of G protein-coupled receptors to uncover a wide range of previously inaccessible drug targets.
Confo Therapeutics, a spin-off of the Vrije Universiteit Brussel and VIB, is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations of these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
EyeD Pharma is developing micro-implants for drug release over a prolonged period of time.
Spica Therapeutics is pioneering Macrophage-Subset targeted therapies
Aphea.Bio is developing the next generation of agricultural biologicals.
